Generics & Biosimilars | Association for Accessible Medicines
In the News - AAM CEO Dan Leonard shares the industry's 2021 outlook with Chain Drug Review.
Learn More
Close
  • Dan Leonard, AAM CEO and President
    2021 Generics and Biosimilars Outlook
    Read AAM CEO Dan Leonard’s 2021 industry outlook—ensuring the sustainability of the generics and biosimilars markets, enhancing the security of the U.S. pharma supply chain and lowering prescription drug costs.
    Read Blog
  • Interactive Savings Map 2020
    Health Care Savings, State by State
    The average state saved $6.1 billion from the use of generic drugs in 2019. How much did your state save?
    Read Blog
  • GRx+Biosims 2020 On-Demand
    Get on-demand access to key sessions of the GRx+Biosims virtual conference.
    Purchase On-Demand
  • A group of five multi-ethnic seniors standing together in a park wearing casual clothing, smiling at the camera.
    Generic Savings Add Up for Patients with Cancer and Other Conditions
    No matter what condition you or your family members are experiencing, generic prescription drugs are saving you money.
    Read Blog
  • #SecureOurMeds
    Plan to Secure Our Medicines
    The U.S. generics and biosimilars industry, makers of 90% of our nation's prescription medicines, has a plan to #SecureOurMeds. We already produce billions of doses domestically and our plan ensures continued patient access through COVID and beyond.
    Watch Video
  • AAM Blueprint U.S. Supply Chain
    Securing the U.S. Rx Supply Chain
    The generic drug industry in the U.S. can expand domestically to increase national security, lessen dependence on any single country and create more jobs. Learn about our plan.
    View Blueprint
  • ""
    Industry Response to COVID-19
    The coronavirus (COVID-19) pandemic is disrupting everyday life around the world and imposing unprecedented stress on our health care system. Here are some responses and resources from the U.S. generics and biosimilars industry.
    Learn More

Working to leave a positive impact on...

Industry Industry We promote competition in the pharmaceutical industry by lowering barriers to entry for manufacturers of generic and biosimilar medicines and combatting anti-competitive abuses by some brand drug companies who put profits before patients. Learn More
People People We measure our success as an industry by the lives we impact. We work to protect the low cost of generic and biosimilar medicines and to drive down the cost of developing new ones, expanding access to as many people as possible. Learn More
Policy Policy We are a trusted partner and established authority within the pharmaceutical field. We provide accurate, timely data to educate policymakers and promote general public knowledge regarding the positive impact of affordable generic and biosimilar medicines. Learn More

About Us

The Association for Accessible Medicines improves access to safe, quality, effective medicine. Better access to medicine is relevant to everybody because, after all, we’re all patients at some point.

Health is the foundation for everything in life. Healthy people are better able to reach their full potential. Generics and biosimilars help more people in more places live healthier and longer.

Who We Are

Recent Updates

Association for Accessible Medicines

601 New Jersey Ave NW, Suite 850
Washington DC 20001

 

202.249.7100
info@accessiblemeds.org

Sign-up for Updates

Receive relevant industry news, event information and the latest resources on biosimilars and generic medicines.

Stay Connected

For the latest updates, follow us on social media.